Skip to main content

Oncology

Lung Cancer, Oncology
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
Wayne Kuznar
Read More
Lung Cancer, Payers' Guide, FDA Approvals, Oncology
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh
Read More
Breast Cancer, Oncology
Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer, Oncology
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
Read More
Lung Cancer, Oncology
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases
Wayne Kuznar
Read More
Breast Cancer, Oncology
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer
Wayne Kuznar
Read More
Lung Cancer, Oncology
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
Read More
Leukemia, Oncology
ASCO 2017: Acute Myeloid Leukemia Highlights
Read More
Multiple Myeloma, Oncology
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
Read More
Page 13 of 27
Results 121 - 130 of 262